Leveraging Advanced Analytical Technologies to Expedite the Development of Antibody Drug Conjugates
A critical step in the development process for an antibody drug conjugate (ADC) is establishing scientifically sound analytical methods that measure key product quality attributes to support pre-clinical activities and downstream clinical release and stability testing. By leveraging key technologies and platform analytical methods, drug developers can expedite an early-phase biologics’ path to IND by removing analytical method development from the critical path.
Join us on an exploration of the analytical characterization required to confidently assess the ID, safety and efficacy of an antibody drug conjugate (ADC). We will start with a practitioners view on the requisite analytics and then shift to several case studies where multiple techniques, from mass spectrometry to light scattering, were used to interrogate these complex protein conjugates.
This webinar promises a comprehensive look at the analytical processes and technologies needed to successfully advance ADC development.
In this webinar you’ll learn:
- Thermal stability and conformational changes associated with the drug-antibody-ratio (DAR)
- How light scattering can be used to study the aggregation of ADCs
- The precision and detail that mass spectrometry provides for ADC characterization
- Justification of application of platform analytical strategies to IgGs and lessons learned
Who should attend:
- Biophysical scientists in government and academia
- Biopharm method development
- Biopharm process development
- Biopharm CMC
Presenter: Colette Quinn, PhD (Director of Marketing and Strategy, Waters|Wyatt Technology)
Colette has worked for Waters Corporation for 13 years, in a number of roles from Applications Scientist and Product Manager before subsequently joining the Wyatt Technology portfolio in 2023.
Prior to joining Waters, she was awarded her Doctorate in Chemistry by Dartmouth College, where she focused on biophysical techniques applied to essential and heavy metal metabolism. Colette is currently working on exciting transformational strategy programs related to more broad adoption of biophysical techniques.
Presenter: Eric Miller, PhD (Sr. Scientific Leader for Analytical Development, Abzena)
Dr. Miller has been in the biopharmaceutical industry since 1996, where he received an initial exposure to antibodies and associated technologies while developing lateral flow diagnostics for the Quidel corporation. Eric has been with Abzena for over 4 years.
In his initial role with the organization Eric served as the Senior Director of the San Diego AMDQC department and later moved to a global position within Abzena’s Scientific Leadership team wherein he serves as analytical subject matter expert.
Prior to joining Abzena, he spent an extensive stint in academia, conducting his PhD studies at Scripps Institution of Oceanography under Professor William Fenical and went on to do postdoctoral research at the California Institute of Technology under Professor Raymond Deshaies and at the Scripps Research Institute under Professor Peter G. Schultz.
Since completing his academic training Eric has provided analytical support for multiple phases of drug development in arenas ranging from early R&D to Commercial.
Moderator: Michelle Taylor (Editor-in-Chief, Laboratory Equipment, Labcompare & Forensic®)
